Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions... Show more
Axon Enterprise holds a commanding position in the public safety technology sector, leading with its integrated ecosystem of TASER conducted energy devices (CEDs), body-worn cameras, in-car cameras, and cloud-based evidence management via Axon Evidence. This "networked" approach creates high switching costs for customers, primarily law enforcement agencies, fostering sticky recurring revenue from software-as-a-service (SaaS) subscriptions. The company commands significant market share in body cameras—estimated over 60% in the U.S.—and digital evidence management, where its platform processes vast amounts of video data securely. Competitive advantages include rapid innovation cycles, such as AI-powered tools for data analysis, and a $14 billion+ bookings backlog that underscores multi-year demand visibility. Medium-term, Axon is expanding internationally and into adjacent markets like fleet management and drones, positioning it to capture growth as agencies modernize amid evolving threats.
The Q1 2026 earnings release on May 6 represents a key near-term event, where management may update on bookings—recently exceeding $7 billion annually—and progress toward 2026 revenue guidance of 27-30% growth. Investors will watch for commentary on new AI tools launched in April 2026 to address data overload in public safety, potentially accelerating software adoption. Ongoing product pipeline advancements, including next-gen TASERs and cloud integrations, could drive contract wins. Analyst activity remains robust: 19 analysts rate AXON a Moderate Buy, with recent targets from JP Morgan at $750 and TD Cowen at $950, reflecting optimism on sustained growth; consensus average hovers near $750, up from prior revisions. These catalysts could boost sentiment if execution aligns with expectations.
The public safety and law enforcement software market is projected to expand from $18 billion in 2025 to over $40 billion by 2033 at a 10.4% CAGR, driven by AI adoption, real-time analytics demand, and modernization of outdated systems. Axon's SaaS-heavy model benefits from this tailwind, as agencies prioritize digital evidence and predictive policing. Macro sensitivities include municipal and state budgets, vulnerable to economic slowdowns or inflation that curb tax revenues and spending on non-essential tech. Rising interest rates could elevate financing costs for multi-year contracts, though Axon's creditworthy customer base and federal grants mitigate this. Geopolitical tensions may spur defense-related demand, while regulatory pushes for body cam transparency favor incumbents like Axon.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality for timely insights. Traders can leverage this engine to inform strategies with data-driven trend signals.
For 2026, Axon targets unprecedented 27-30% revenue growth, building on SaaS acceleration and a $14 billion backlog, with analysts forecasting robust EPS expansion. Long-term themes include AI transitions for automated redaction and analytics, international market penetration, and margin expansion via scale—potentially reaching 25%+ adjusted EBITDA margins by 2028 per company aspirations. Cost efficiencies from cloud migration and supply chain optimization support sustainability, though competitive threats from smaller tech entrants loom. Regulatory developments around data privacy and police tech standards could shape adoption. Consensus analyst expectations remain optimistic, with price targets averaging $750 and highs to $1,000, emphasizing structural demand in public safety. Capital allocation will focus on R&D and tuck-in M&As (mergers and acquisitions) to bolster the ecosystem.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SLTY | 25.66 | 0.26 | +1.02% |
| YieldMaxTM Ultra Short Opt Inc Strat ETF | |||
| PSMR | 31.96 | N/A | N/A |
| Pacer Swan SOS Moderate (April) ETF | |||
| PCR | 20.06 | -0.03 | -0.17% |
| Simplify VettaFi Private Credit Stgy ETF | |||
| ISD | 12.95 | -0.24 | -1.82% |
| PGIM High Yield | |||
| EDV | 61.47 | -1.35 | -2.15% |
| Vanguard Extended Duration Trs ETF | |||
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | +0.95% | ||
| TECH - AXON | 61% Loosely correlated | -3.22% | ||
| VCYT - AXON | 58% Loosely correlated | -1.08% | ||
| BEAM - AXON | 57% Loosely correlated | -5.42% | ||
| SEER - AXON | 56% Loosely correlated | -1.71% | ||
| ADPT - AXON | 56% Loosely correlated | -2.66% | ||
More | ||||
The RSI Indicator for AXON moved out of oversold territory on April 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In of the 26 cases the stock moved higher. This puts the odds of a move higher at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on April 16, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in of 377 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 288 cases where AXON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Momentum Indicator moved below the 0 level on May 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AXON broke above its upper Bollinger Band on May 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 66, placing this stock worse than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.937) is normal, around the industry mean (7.675). P/E Ratio (158.016) is within average values for comparable stocks, (62.735). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.430). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (10.858) is also within normal values, averaging (95.986).